2021 Oct 1 : 101011.
PMCID: PMC8483988 - Jessica Rose, PhD, MSc, BSc1, and Peter A. McCullough, MD, MPH1
A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products
As of May 18th, 2021, 600,000 children aged 12-15 had been injected with COVID-19 products
3 . [
14 ] The CDC estimated that 3,430,741 children aged 12-15 have received at least one dose of the COVID-19 products as of June 7th, 2021.
4 Since 1 per 100,000 children per year are affected by myocarditis
5 then, statistically, we would expect ∼5 myocarditis cases if we calculate the expected number of cases using the June 7th CDC sample. To date (up to and including July 2nd, 2021), 97 children aged 12-15 have had reports submitted to VAERS representing 17.4% of all myocarditis reports – and these are merely the cases that we are aware of. Thus, after 8 weeks of roll-out into the 12-15 years-old age group, we are at ∼19 times the expected number of cases within this sample. Thus, the number of VAERS-reported cases far outnumber what would typically be expected to date. It is important to note that of the 559 myocarditis VAERS reports, 6 died (1.1%) and 33% of these deaths were in individuals under 20 years of age: 1 individual was 13 and one was 19 years of age.
Data right-skewed in statistically significant way toward young males
In addition to very high rates of myocarditis cases in children aged 12-15, these rates are observed much more commonly in males.
Figure 4 shows the distribution of myocarditis cases by age in males versus females. The distribution is right-skewed toward the younger age groups, and this is statistically significant (I=1.28), and males represent 80% of all cases. The most frequent occurrences were in 15-year-old boys (N= 44) and 18-year-old girls (N= 6).
Since the high-risk age population for myocarditis is from puberty through early 30s, myocarditis should be considered diagnostically in any young adult who experiences shortness of breath, palpitations or chest pain following injection with dose 1 of any COVID-19 injectable product. It is notable that chest pain is a prevalent tandem AE (25% of individuals who filed myocarditis reports into VAERS also experienced chest pain following dose 1) and this may not be acknowledged by a teenager, or even a medical professional, as a warning sign of cardiac insult. The data is right-skewed toward the younger ages, and this is statistically significant (I=1.2).
